Advertisement

Topics

FDA finds another carcinogen in valsartan products

04:59 EDT 14 Sep 2018 | BioPharmaDive

The impurities continue a summer-long effort by regulators to assess the risk from tainted API of the heart drug.

Original Article: FDA finds another carcinogen in valsartan products

NEXT ARTICLE

More From BioPortfolio on "FDA finds another carcinogen in valsartan products"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...